Filter your search
- $1,875.00 – $3,750.00Each year in the United States, more than 500,000 people with coronary artery disease are treated with percutaneous transluminal coronary angioplasty (PTCA). Unfortunately, restenosis occurs within three to six months in 40% to 50% of PTCA patients due to either thrombosis or abnormal tissue growth. As a result, restenosis constitutes the major limitation to the […]April 1, 2003$6,000.00 – $12,000.00Once a public health problem pegged for easy elimination, infectious diseases continue to be the leading cause of death worldwide. Despite improved methods of treating and preventing infection, including potent antibiotics, comprehensive immunization, and modern sanitation, infection still accounts for much serious illness, even in highly industrialized countries. Use this new Kalorama Information 3-volume series […]April 1, 2003$1,875.00 – $3,750.00This report analyzes the world markets for human antiviral medications, focusing on the current market for and the development of drugs that are used to directly combat and treat viruses viral infections. For the purposes of this report, antivirals are drugs used to directly treat viral infection after it occurs. The report does not discuss […]April 1, 2003$371.00 – $742.00Diabetes monitoring and therapeutics to manage the disease and its complications continues to be an attractive market for many manufacturers. However, the factors that affect the potential of diabetes markets—including population demographics and the attitude of healthcare policy makers and clinicians—can seem like shifting sands from one country to the next. That’s why Kalorama is […]March 1, 2003$2,812.00 – $5,625.00During the last 25 years, there have been unprecedented advancements in the area of women’s health and there is widespread recognition of the importance of addressing conditions that overwhelmingly affect women. Likewise, pharmaceutical marketers have increasingly understood the potential that the women’s health market represents and the increasing clout female consumers are wielding in the […]March 1, 2003$250.00 – $5,250.00The world of analytical microchips is the fastest growing technology segment in the life sciences today. The range of applications to which these miniature laboratories may be directed is very broad–covering fields as different as pharmaceutical development, food testing, clinical diagnostics, forensics, and environmental analysis. Moreover, while the number of such products is currently limited, […]March 1, 2003$596.00 – $1,192.00To succeed in the diagnostics market of the 21st Century, a company has to have either a strong niche position in a particular market segment or be a jack of all trades. In either case, a full or comprehensive menu is critical. Why reinvent the wheel? Most tests and systems are already available somewhere, offered […]February 1, 2003$1,121.00 – $1,717.00In the summer of 2002, Kalorama Information released a major study on non-psychiatric neurotherapeutic drug markets. At almost 500 pages, the resulting report covered a broad range of neurological agents comprehensively and in depth; however, the breadth and authority of the results proved to be more information than some marketers needed. Smaller biopharmaceutical concerns—some of […]January 1, 2003$2,500.00 – $5,000.00Antibiotic development has never proceeded at this pace or with this much urgency. Demand for effective antibacterial compounds is growing rapidly and companies are trying to fill their pipelines with products that can meet the challenges of increasingly stubborn infectious agents. By far the largest of the anti-infective segments, antibacterials represent approximately 65% of the […]January 1, 2003$995.00 – $5,990.00Since our last edition of this report in 2007, the oral drug delivery market is the largest segment of the drug delivery market, and there’s no sign that it is slowing down. With pharmaceutical companies increasingly turning to drug delivery to extend the revenue-earning lifetime of their biggest products, and seeking to tap into the […]July 1, 2000